The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...

Specialized sarcoma centers enhance coordinated care for young adults, although travel and financial barriers persist, Dr. Vinayak Venkataraman stated. Specialized, multidisciplinary care at ...

The positions in the table below reflect the Cure Alveolar Soft Part Sarcoma International's position overall, domestically, within their sector, and in various subject areas based on their Share.

Sean Baute welcomes the Sarcoma Foundation of America to the Listens Live! studio to highlight the 2025 Race to Cure Sarcoma.